Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory (2021 - 2025)

Historic Inventory for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $122.8 million.

  • Apellis Pharmaceuticals' Inventory rose 145.47% to $122.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.8 million, marking a year-over-year increase of 145.47%. This contributed to the annual value of $81.4 million for FY2024, which is 4438.17% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Inventory stood at $122.8 million for Q3 2025, which was up 145.47% from $121.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Inventory ranged from a high of $161.3 million in Q1 2024 and a low of $1.7 million during Q3 2021
  • Its 5-year average for Inventory is $84.7 million, with a median of $85.6 million in 2022.
  • In the last 5 years, Apellis Pharmaceuticals' Inventory soared by 346308.88% in 2022 and then plummeted by 4886.75% in 2025.
  • Apellis Pharmaceuticals' Inventory (Quarter) stood at $16.3 million in 2021, then skyrocketed by 426.3% to $85.7 million in 2022, then surged by 70.76% to $146.4 million in 2023, then tumbled by 44.38% to $81.4 million in 2024, then skyrocketed by 50.88% to $122.8 million in 2025.
  • Its last three reported values are $122.8 million in Q3 2025, $121.0 million for Q2 2025, and $82.5 million during Q1 2025.